Racial and Ethnic Disparities in the Use and Outcomes With WATCHMAN FLX: A SURPASS Analysis of the NCDR Left Atrial Appendage Occlusion Registry
Authors:
- Oluseun O. AlliOAOluseun O. Alli
- Jalaj GargJGJalaj Garg
- Brian C. BoursiquotBBBrian C. Boursiquot
- Samir R. KapadiaSKSamir R. Kapadia
- Robert W. YehRYRobert W. Yeh
- Matthew J. PriceMPMatthew J. Price
- Jonathan P. PicciniJPJonathan P. Piccini
- Devi G. NairDNDevi G. Nair
- Jonathan C. HsuJHJonathan C. Hsu
- Douglas N. GibsonDGDouglas N. Gibson
- Dominic AlloccoDADominic Allocco
Open Access
- 22 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e036406
Abstract
Background: Left atrial appendage occlusion (LAAO) is increasingly used as an alternative to oral anticoagulation for stroke prevention in select patients with atrial fibrillation. Data on outcomes in racial and ethnic minority individuals are limited. This analysis assessed differences in the use and outcomes of LAAO by race and ethnicity in a large national registry. Methods and Results: This analysis acquired data on patients who underwent WATCHMAN FLX implantation from the retrospective NCDR (National Cardiovascular Data Registry) LAAO registry through September 2022. All patients with an attempted WATCHMAN FLX implantation and known race and ethnicity were included. Baseline characteristics and 1‐year event rates were compared. A total of 97 185 patients were analyzed; 87 339 were White individuals (90%), 3750 Black individuals (3.9%), and 2866 Hispanic individuals (Hispanic/Latinx), 2.9%). Black and Hispanic patients were younger, with a higher incidence of prior stroke and significant bleeding compared with White patients. Black and Hispanic patients were treated with LAAO in smaller numbers relative to their proportion of the US population. Rates of procedural success were similar between groups. Though direct oral anticoagulants were prescribed in most patients across the groups, dual and single antiplatelet therapy were prescribed more often in Black patients. Black patients had significantly higher rates of 1‐year death and bleeding compared with White and Hispanic patients. Conclusions: Patients from racial and ethnic minority groups comprise a disproportionately small fraction of all patients who undergo LAAO. Black and Hispanic patients were younger but had significantly higher comorbidities compared with White patients. Procedural success was similar among the groups, but Black patients experienced higher rates of death and bleeding at 1 year.Keywords
This publication has 33 references indexed in Scilit:
- Temporal Changes in Racial and Ethnic Disparities in the Utilization of Left Atrial Appendage Occlusion in the United StatesThe American Journal of Cardiology, 2023
- American Indians and atrial fibrillationHeart Rhythm O2, 2022
- Racial and ethnic differences in implantable cardioverter-defibrillator patient selection, management, and outcomesHeart Rhythm O2, 2022
- Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial FibrillationJAMA Cardiology, 2022
- Development and validation of an automated algorithm for end point adjudication for a large U.S. national registryAmerican Heart Journal, 2022
- Racial disparities and democratization of health care: A focus on TAVR in the United StatesAmerican Heart Journal, 2020
- Racial Differences in Atrial Fibrillation Epidemiology, Management, and OutcomesCurrent Treatment Options in Cardiovascular Medicine, 2019
- Differential Impact of Risk Factors in Blacks and Whites in the Development of Atrial Fibrillation: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) StudyJournal of Racial and Ethnic Health Disparities, 2016
- Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation RegistryAmerican Heart Journal, 2016
- Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial FibrillationJAMA, 2014